Opthea Ltd has released a press release.
Opthea Completes Patient Dosing in Phase 2a DME Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Opthea
- Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME
- Opthea Equity Raising Presentation
- Opthea Presentation for Ophthalmology Innovation Summit
- Opthea Receives A$14.6m R&D Tax Incentive
- Opthea Presentation for EURETINA Congress
Later from Opthea
- Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
- S&P DJI Announces June 2020 Quarterly Rebalance
- Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)
- Opthea Completes Successful FDA and EMA Meetings for Phase 3
- Opthea Announces Plans for Potential US listing and IPO
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea